Bio-Path Hldgs Inc Financials
This page shows Bio-Path Hldgs Inc (BPTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Bio-Path’s business model is a cash-funded research program where new financing, not revenue, keeps development activity going year after year.
FY2024’s smaller net loss did not make the company self-funding: operating cash burn was$10.6M , almost entirely offset by$10.7M of financing inflow. What can look like heavy leverage is mostly a near-exhausted equity base story, because liabilities were only$3.7M while equity had shrunk to$154K .
The expense mix is still research-led, with R&D at
Liquidity has tightened sharply over the last two valid years: cash moved from
Financial Health Signals
Bio-Path Hldgs Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Bio-Path Hldgs Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Bio-Path Hldgs Inc reported a net loss of $9.9M while operations used $10.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Bio-Path Hldgs Inc's EBITDA was -$11.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.2% from the prior year.
Bio-Path Hldgs Inc reported -$9.9M in net income in fiscal year 2024. This represents an increase of 38.5% from the prior year.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Bio-Path Hldgs Inc held $1.2M in cash as of fiscal year 2024; long-term debt is not reported for that period.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
Bio-Path Hldgs Inc's ROE was -6424.7% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 2778.9 percentage points from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Capital Allocation
Bio-Path Hldgs Inc invested $7.3M in research and development in fiscal year 2024. This represents a decrease of 37.2% from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
BPTH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $37K+184.6% | $13K | $0 | $0 | $0 | $0 | $0 | N/A |
| R&D Expenses | $7.3M-37.2% | $11.6M+26.7% | $9.2M+55.1% | $5.9M-10.2% | $6.6M+43.5% | $4.6M-0.4% | $4.6M-16.0% | $5.5M+0.1% | $5.5M+81.3% | $3.0M+85.3% | $1.6M+7.3% | $1.5M+34.1% | $1.1M | N/A | N/A |
| SG&A Expenses | $4.7M+10.9% | $4.2M-10.6% | $4.7M+4.5% | $4.5M+4.7% | $4.3M+5.4% | $4.1M+21.6% | $3.4M-4.1% | $3.5M+16.9% | $3.0M+22.3% | $2.5M-9.2% | $2.7M+66.1% | $1.6M+65.8% | $986K-19.5% | $1.2M+8.7% | $1.1M |
| Operating Income | -$12.0M+24.3% | -$15.8M-14.0% | -$13.9M-33.1% | -$10.4M+4.3% | -$10.9M-25.5% | -$8.7M-1.2% | -$8.6M+4.2% | -$9.0M-5.8% | -$8.5M-54.5% | -$5.5M-20.8% | -$4.5M-38.9% | -$3.3M-26.6% | -$2.6M-9.2% | -$2.4M-1.7% | -$2.3M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Net Income | -$9.9M+38.5% | -$16.1M-15.9% | -$13.9M-32.8% | -$10.4M+4.1% | -$10.9M-26.5% | -$8.6M-0.2% | -$8.6M-22.2% | -$7.0M-4.0% | -$6.8M-23.5% | -$5.5M-21.0% | -$4.5M-38.4% | -$3.3M-26.5% | -$2.6M-9.3% | -$2.4M-13.5% | -$2.1M |
| EPS (Diluted) | -$4.12 | -$33.63+11.8% | -$38.12 | -$1.55 | -$2.83 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
BPTH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.9M+20.6% | $3.2M-79.8% | $16.0M-39.9% | $26.6M+61.3% | $16.5M-27.3% | $22.7M+790.4% | $2.5M-71.3% | $8.9M-27.4% | $12.2M+13.4% | $10.8M-30.5% | $15.5M+204.8% | $5.1M+116.7% | $2.3M-27.5% | $3.2M+3.9% | $3.1M |
| Current Assets | $3.8M+24.1% | $3.0M-80.5% | $15.6M-40.3% | $26.1M+63.8% | $16.0M-27.4% | $22.0M+928.1% | $2.1M-71.2% | $7.4M-30.2% | $10.7M+11.0% | $9.6M-32.0% | $14.1M+284.9% | $3.7M+375.3% | $772K-33.1% | $1.2M+79.0% | $644K |
| Cash & Equivalents | $1.2M+11.5% | $1.1M-89.9% | $10.4M-56.3% | $23.8M+72.8% | $13.8M-32.7% | $20.4M+1934.5% | $1.0M-83.2% | $6.0M-36.4% | $9.4M+5.9% | $8.9M-36.1% | $13.9M+290.2% | $3.6M+565.1% | $534K-43.9% | $952K+299.2% | $239K |
| Total Liabilities | $3.7M+34.2% | $2.8M+54.6% | $1.8M+61.7% | $1.1M-20.9% | $1.4M-10.7% | $1.6M+18.6% | $1.3M+67.8% | $791K-80.0% | $4.0M+322.2% | $937K+66.7% | $562K+90.6% | $295K-10.4% | $329K+4.1% | $316K+28.1% | $247K |
| Current Liabilities | $3.3M+72.9% | $1.9M+13.2% | $1.7M+75.8% | $958K-18.0% | $1.2M-6.0% | $1.2M-6.3% | $1.3M+67.8% | $791K-24.7% | $1.1M+12.1% | $937K+66.7% | $562K+90.6% | $295K-10.4% | $329K+4.1% | $316K+28.1% | $247K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 | N/A |
| Total Equity | $154K-65.1% | $441K-96.9% | $14.2M-44.3% | $25.5M+68.9% | $15.1M-28.5% | $21.1M+1631.2% | $1.2M-84.9% | $8.1M-2.1% | $8.2M-16.1% | $9.8M-34.2% | $14.9M+211.9% | $4.8M+137.4% | $2.0M-30.9% | $2.9M+1.9% | $2.9M |
| Retained Earnings | -$117.5M-9.2% | -$107.6M-17.6% | -$91.5M-17.9% | -$77.7M-15.5% | -$67.2M-19.3% | -$56.3M-18.0% | -$47.7M-21.9% | -$39.2M-21.9% | -$32.1M-26.6% | -$25.4M-27.4% | -$19.9M | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
BPTH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.6M+8.3% | -$11.5M+23.6% | -$15.1M-52.3% | -$9.9M+9.5% | -$11.0M-31.1% | -$8.4M-36.5% | -$6.1M+23.0% | -$8.0M+2.3% | -$8.1M-62.8% | -$5.0M-31.1% | -$3.8M-65.0% | -$2.3M-16.0% | -$2.0M-73.4% | -$1.1M-0.2% | -$1.1M |
| Capital Expenditures | N/A | N/A | $21K-70.0% | $70K | N/A | $0-100.0% | $17K-96.8% | $538K+59.2% | $338K | $0-100.0% | $123K | $0 | $0 | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$15.1M-51.4% | -$10.0M | N/A | -$8.4M-36.2% | -$6.1M+27.7% | -$8.5M-0.1% | -$8.5M-69.6% | -$5.0M-27.0% | -$3.9M-70.3% | -$2.3M-16.0% | -$2.0M | N/A | N/A |
| Investing Cash Flow | N/A | N/A | -$21K+70.0% | -$70K | N/A | $0+100.0% | -$17K+96.8% | -$538K-59.2% | -$338K | N/A | N/A | $0+100.0% | -$25K+85.3% | -$170K+26.0% | -$230K |
| Financing Cash Flow | $10.7M+385.5% | $2.2M+27.0% | $1.7M-91.3% | $20.0M+366.4% | $4.3M-84.6% | $27.8M+2254.5% | $1.2M-76.8% | $5.1M-43.5% | $9.0M | N/A | N/A | $5.3M+233.1% | $1.6M-21.3% | $2.0M+93.8% | $1.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BPTH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -24232.4% | -65192.3% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -18981.1% | -51923.1% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -6424.7%-2778.9pp | -3645.8%-3548.0pp | -97.8%-56.8pp | -41.0%+31.2pp | -72.2%-31.4pp | -40.8%+663.9pp | -704.7%-617.6pp | -87.1%-5.1pp | -81.9%-26.2pp | -55.7%-25.4pp | -30.3%+38.0pp | -68.3%+59.9pp | -128.2%-47.1pp | -81.1%-8.3pp | -72.7% |
| Return on Assets | -254.8%+244.5pp | -499.3%-412.5pp | -86.8%-47.5pp | -39.3%+26.7pp | -66.0%-28.1pp | -38.0%+299.3pp | -337.3%-258.0pp | -79.3%-23.9pp | -55.4%-4.5pp | -50.8%-21.6pp | -29.2%+35.1pp | -64.3%+45.9pp | -110.2%-37.1pp | -73.1%-6.2pp | -67.0% |
| Current Ratio | 1.15-0.5x | 1.60-7.7x | 9.27-18.0x | 27.29+13.6x | 13.65-4.0x | 17.68+16.1x | 1.61-7.8x | 9.40-0.7x | 10.15-0.1x | 10.24-14.9x | 25.12+12.7x | 12.44+10.1x | 2.34-1.3x | 3.65+1.0x | 2.61 |
| Debt-to-Equity | 24.21+17.9x | 6.30+6.2x | 0.13+0.1x | 0.040.0x | 0.090.0x | 0.07-1.0x | 1.09+1.0x | 0.10-0.4x | 0.48+0.5x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.00-0.1x | 0.09 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -22959.5% | -65276.9% | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Bio-Path Hldgs Inc Ranks
Frequently Asked Questions
Is Bio-Path Hldgs Inc profitable?
No, Bio-Path Hldgs Inc (BPTH) reported a net income of -$9.9M in fiscal year 2024.
What is Bio-Path Hldgs Inc's EBITDA?
Bio-Path Hldgs Inc (BPTH) had EBITDA of -$11.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bio-Path Hldgs Inc's return on equity (ROE)?
Bio-Path Hldgs Inc (BPTH) has a return on equity of -6424.7% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Bio-Path Hldgs Inc's operating cash flow?
Bio-Path Hldgs Inc (BPTH) recorded an outflow of $10.6M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Bio-Path Hldgs Inc's total assets?
Bio-Path Hldgs Inc (BPTH) had $3.9M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Bio-Path Hldgs Inc spend on research and development?
Bio-Path Hldgs Inc (BPTH) invested $7.3M in research and development during fiscal year 2024.
What is Bio-Path Hldgs Inc's current ratio?
Bio-Path Hldgs Inc (BPTH) had a current ratio of 1.15 as of fiscal year 2024, which is considered adequate.
What is Bio-Path Hldgs Inc's debt-to-equity ratio?
Bio-Path Hldgs Inc (BPTH) had a debt-to-equity ratio of 24.21 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bio-Path Hldgs Inc's return on assets (ROA)?
Bio-Path Hldgs Inc (BPTH) had a return on assets of -254.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Bio-Path Hldgs Inc's cash runway?
Based on fiscal year 2024 data, Bio-Path Hldgs Inc (BPTH) had $1.2M in cash against an annual operating cash burn of $10.6M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Bio-Path Hldgs Inc's Piotroski F-Score?
Bio-Path Hldgs Inc (BPTH) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bio-Path Hldgs Inc's earnings high quality?
Bio-Path Hldgs Inc (BPTH) reported a net loss of $9.9M while operations used $10.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.